Adma Biologics Inc Net debt/EBITDA
Quel est le Net debt/EBITDA de Adma Biologics Inc?
Le Net debt/EBITDA de Adma Biologics Inc est -2.89
Quelle est la définition de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA des entreprises dans Health Care secteur sur NASDAQ par rapport à Adma Biologics Inc
Que fait Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Entreprises avec net debt/ebitda similaire à Adma Biologics Inc
- Alps Alpine Co a Net debt/EBITDA de -2.93
- Plug Power a Net debt/EBITDA de -2.93
- Watford a Net debt/EBITDA de -2.92
- Ross Stores a Net debt/EBITDA de -2.92
- u-blox AG a Net debt/EBITDA de -2.92
- Fastly Inc a Net debt/EBITDA de -2.91
- Adma Biologics Inc a Net debt/EBITDA de -2.89
- Neo Performance Materials a Net debt/EBITDA de -2.89
- Decmil a Net debt/EBITDA de -2.89
- Taylor Wimpey Plc a Net debt/EBITDA de -2.89
- Desktop Metal a Net debt/EBITDA de -2.89
- Nanostring Technologies Inc a Net debt/EBITDA de -2.89
- Rekor Systems Inc a Net debt/EBITDA de -2.89